Levosimendan was associated with more frequent hypotension and cardiac arrhythmias during the infusion period and a numerically higher risk of death across the @ trials ( @ of @ on a regimen of levosimendan vs. @ of @ on a regimen of placebo at @ days , p = @ ) .